BioCentury
ARTICLE | Clinical News

TP10: Phase IIb

February 23, 2004 8:00 AM UTC

AVAN will start this quarter a double-blind, placebo-controlled, U.S. Phase IIb trial in 300 female patients. In a Phase II trial, TP10 significantly decreased the primary endpoint of the composite in...